Introduction
Neuronal nicotinic acetylcholine receptors (nAChRs) are a heterogeneous family of pentameric ligand-gated cation channels, classified according to subunit composition and pharmacology into α-bungarotoxin sensitive, homopentameric α7 receptors, and into α-bungarotoxin insensitive, heteropentameric, non-α7 nAChRs (Albuquerque et al., 2009 ). The latter can be assembled by combinations of different α and β nicotinic subunits, among which the most prevalent is the α4β2 combination (α4β2*, with the asterisk indicating the possible participation of additional subunits). The prolonged exposure to nicotine has been consistently shown to increase nAChR binding, both in cigarette smokers (Mukhin et al., 2008; Staley et al., 2006) and in animal models of nicotine intake (Marks et al., 1983; Schwartz and Kellar, 1983 ). This neurochemical adaptation has been associated with several nicotine-induced behaviours, including self-administration (Metaxas et al., 2010) , reward sensitisation (Hilario et al., 2012) , locomotor activity tolerance (McCallum et al., 2006) , and nicotine withdrawal (Gould et al., 2012) .
Adenosine is an ubiquitous purine neuromodulator, which exerts its effects by activating four types of G-protein coupled receptors, namely A 1 , A 2A , A 2B , and A 3 adenosine receptors.
Among them, adenosine A 2A receptors (A 2 ARs) have attracted much interest as potential modulators of the effects of nicotine, both because of their predominant localization in brain circuitries that are involved in reinforcement (Ferre et al., 2007) , and due to the altered behavioural phenotype that A 2A R knockout (KO) mice exhibit in response to nicotine. For instance, nicotine-induced conditioned place preference and dopamine release in the nucleus accumbens are attenuated in mice with genetic ablation of the adenosine A 2A R gene, suggesting that A 2A Rs contribute to nicotine reward (Castane et al., 2006) . Moreover, the aversive response to nicotine withdrawal is blocked in A 2A R KO mice, indicating that A 2A Rs *Manuscript Click here to view linked References modulate the motivational states associated with the cessation of chronic, but not acute, nicotine intake (Grieder et al., 2012) .
There is considerable in vitro evidence suggesting that A 2A Rs regulate cholinergic neurotransmission in the central nervous system. Functional A 2A Rs are expressed on cholinergic nerve terminals (Preston et al., 2000; Tozzi et al., 2011) , and their activation increases the release of acetylcholine (ACh) in the hippocampus (Rebola et al., 2002; Rodrigues et al., 2008) and the striatum (Gubitz et al., 1996; Kirkpatrick and Richardson, 1993) . A 2A R-mediated ACh release in the rodent striatum has also been demonstrated in vivo, suggesting that striatal cholinergic neurotransmission is tonically influenced by adenosine acting on A 2A Rs . Moreover, electrophysiological recordings from cell lines or neuronal cultures co-expressing A 2A and nAChRs, reveal that tonic A 2A R activation is required for sustaining the functional response of nAChRs to repeated ACh or nicotine exposure, indicating that A 2A Rs may confer a gain of function to nAChRs (Di Angelantonio et al., 2011) .
Despite the prominent role of adenosine A 2A Rs in regulating cholinergic neurotransmission, nAChR function, and nicotine-induced behaviour, the potential modulatory effects of A 2A Rs on the expression of distinct nAChR subtypes remain unknown. Based on the evidence suggesting that A 2A R activation tonically regulates cholinergic neurotransmission and nAChR function, we hypothesized that compensatory neuroadaptations might occur in the nicotinic cholinergic system when A 2A Rs are compromised. To test this hypothesis, the distribution and binding densities of α4β2* and α7 nAChRs were quantified in brain sections of drugnaïve, wild-type (WT) and homozygous (-/-) A 2A R KO mice, using quantitative receptor autoradiography. In addition, as A 2A R activity regulates the functional and behavioural response to nicotine, we reasoned that adenosine A 2A Rs may also modulate the neuroadaptive changes that occur in nAChR binding, following chronic nicotine treatment. To investigate the effects of A 2A Rs on nicotine-induced upregulation, α4β2* and α7 nAChRs binding levels were measured in brain sections of WT and A 2A R KO mice, following 14 days of nicotine administration.
Materials and methods

Generation of the adenosine A 2A R KO mouse and experimental conditions
All animal care and experimental procedures complied with protocols approved by the UK Home Office, Animals (Scientific Procedures) Act, 1986 . All studies are reported in accordance with the ARRIVE guidelines (McGrath et al., 2010) , and were designed to minimise suffering and to reduce the number of animals used. CD1 adenosine A 2A R KO mice, originally generated by Ledent et al. (1997) , were obtained from the breeding colony of the University of Surrey, as previously detailed (Bailey et al., 2004a) . Briefly, mutant mice were obtained from heterozygote breeding pairs, which originated from the individual crossing of a number of heterozygote males from the existing colony, each with a WT female of the CD1 strain, which was purchased from an external supplier (Charles River, UK). All mice were genotyped at weaning using a polymerase chain reaction (PCR) based method.
Tail tip samples were collected at 3 weeks of age, and DNA was extracted using the DNeasy tissue kit, according to the manufacturers' instructions (QIAGEN, Germany).
Adult, 8-12 weeks old, male CD1 mice were used in all experiments (total number: 36). The animals were individually housed in a temperature controlled environment, under a 12 h light/dark cycle (lights on: 7.00 am). Food and water were available ad libitum.
Confirmation of genotype with autoradiographic binding
To confirm the genotype of the animals used in the present studies, brain sections of WT and KO mice were processed for A 2A R binding according to Bailey et al. (2004b) . Briefly, sections were pre-incubated for 30 min in 170 mM Tris-HCl buffer, containing 1 mM EDTA (pH 7.4, room temperature). Sections were then incubated for 2 h at room temperature, in 170 mM Tris-HCl buffer, containing 10 nM [ 3 H]CGS21680 (PerkinElmer; specific activity 30
Ci/mmol), 10 nM MgCl 2 , and 2 U/ml adenosine deaminase (pH 7.4). Incubations were terminated by 3 x 5 min washes into ice cold 50 mM Tris buffer (pH 7.4), and a rapid rinse in ice cold water. Radioligand bound sections were apposed for a period of 3 weeks to Kodak
BioMax MR-1 film (Sigma-Aldrich, UK).
Quantitative autoradiography of α7 and α4β2* nAChRs in drug-naïve WT and adenosine A 2A R KO CD1 mice
To examine whether compensatory changes occur in different subtypes of nAChR after the genetic deletion of adenosine A 2A Rs, quantitative autoradiography of α7 and α4β2* nAChRs was performed using brain sections from drug-naïve, WT and adenosine A 2A R KO CD1 mice (n=6). Animals were killed by cervical dislocation and brains were immediately removed and frozen in isopentane on dry ice. The brains were stored at -80 o C for a maximum period of 1 month before being processed for quantitative autoradiography of α7 and α4β2* nAChRs, as detailed in Metaxas et al. (2012) . Tissue sectioning was carried out at -21 °C, using a Microm HM505E cryostat (Carl Zeiss, Germany). Multiple, adjacent 20 µm coronal brain sections were collected at 300 µm intervals, from rostral to caudal levels.
For heteromeric nAChRs, sections were pre-incubated for 10 min at room temperature in Incubations were terminated by 2 x 10 min washes into ice-cold 50 mM Tris-HCl buffer (pH 7.4), and a rapid rinse in ice-cold water. Radioligand bound sections were apposed to BioMax MR-1 film for 24 h.
For homopentameric α7 nAChRs, sections were pre-incubated for 30 min at room temperature in assay buffer (50 mM Tris-HCl, 1% w/v BSA; pH 7.4). Adjacent, non-specific binding sections were pre-incubated in the same buffer, containing 1 mM of (-) nicotine hydrogen tartrate. Sections were then incubated for a period of 3 h at room temperature in assay buffer, containing 3 nM of [ 125 I]α-bungarotoxin (specific activity 250 Ci mmol -1 , GE Healthcare). Adjacent sections were incubated in the same buffer, in the presence of 1 mM (-) nicotine hydrogen tartrate. Specific α7 nAChR binding was calculated after the subtraction of NSB from total binding values. Incubations were terminated by 3 x 10 min washes into ice cold 50 mM Tris buffer (pH 7.4), and a rapid rinse in ice cold water. Sections were apposed to Kodak BioMax MR-1 film for a period of 7 days.
Quantitative analysis of receptor binding was performed by video-based computerised densitometry using an MCID image analyser (InterFocus Imaging, UK), as detailed previously (Kitchen et al., 1997) . Briefly, optical density values were quantified from 14 C microscales, which had been cross-calibrated to 125 I standards of known radioactive concentration (GE Healthcare, UK). The optical density values were subsequently entered with their corresponding radioactivity values into a calibration table, and the relationship between radioactivity and optical density was determined using the MCID software. All brain structures were identified by reference to the mouse atlas of Franklin and Paxinos (2001) .
Chronic nicotine treatment
Minipump preparation and implantation
Saline or nicotine hydrogen salt (Sigma-Aldrich, UK) were administered to WT and adenosine A 2A R KO CD1 mice, using mini osmotic pumps (n=5-7; ALZET ® 2002 model, Charles River, UK). The concentration of the nicotine salt solution was adjusted according to animal weight, to achieve a daily nicotine dose of 7.8 mg kg -1 (free-base weight), which was delivered for a period of 14 days, at a rate of 0.5 µl h -1 . This dose was chosen for its ability to induce upregulation of nAChR binding in the mouse brain (Davis et al., 2005; Marks et al., 2004) , and to produce blood plasma levels of nicotine comparable with the human condition (see results).
For minipump implantation, animals were anaesthetised with an isoflurane/oxygen vapour mixture (3.5%-4.5%; Isoflo, Abbott Laboratories Ltd, UK), which was delivered at a flow rate of 450 ml min -1 (U400 unit, Royem Scientific, UK). Under aseptic conditions, a single incision was made along the midline of the back, to reveal the subcutaneous layer. Blunt ended scissors were used to form a subcutaneous compartment, in which an osmotic minipump was placed parallel to the spine, with the flow moderator pointing away from the incision, which was subsequently closed using 1-2 Michelle clips. Mice were allowed to recover from the operating procedure in a heated chamber before being transferred to their home cage, where they remained for the duration of this study. 
Quantitative autoradiography
Determination of plasma nicotine and cotinine levels
Following cervical dislocation, ~ 800 μl of trunk blood were collected from each mouse into ice-cold, heparinized tubes, and plasma was immediately obtained by 20 min centrifugation at 2,500 rpm in a refrigerated centrifuge. Samples were subsequently frozen and transported in dry ice to ABS Laboratories Ltd, UK, for analysis of nicotine and cotinine levels using capillary column gas chromatography with nitrogen-phosphorus detection (Feyerabend and Russell, 1990) . The detection limit for nicotine and cotinine was 0.1 ng ml -1 .
Statistical analysis
Two-way ANOVA for the factors genotype and region was used for the comparison of quantitative measures of α4β2* and α7 nAChRs in brain regions of drug naïve, WT and adenosine A 2A R KO mice.
Three-way ANOVA for the factors treatment, genotype and brain region was used to compare receptor binding levels in saline and nicotine treated, WT and adenosine A 2A R KO animals.
Where ANOVA yielded significant main effects, Fisher's LSD post hoc analysis was used to investigate differences in radioligand binding between groups in individual brain regions.
Plasma levels of nicotine and cotinine were compared between nicotine treated WT and A 2A R KO mice using two-tailed Student's t-tests. Statistical significance was set at alpha level of <0.05. All data were analysed using the Statistica software (Statsoft Inc., France), and are presented as the mean ± SEM of n animals/group.
Results
Confirmation of genotype
Labeling of A 2A R binding sites by [ 3 H]CGS21680 was dense in the striatum of WT mice, and completely absent in the brains of homozygous knockout mice, confirming the genotype of the animals used in this study (Supplementary Figure S1 ).
Lack of genotype effect on neuronal nAChR binding levels in naïve CD1 mice
To [ 125 I]α-bungarotoxin binding to α7 nAChRs was dense in nuclei of the hypothalamus, hippocampus, and the amygdala, but virtually absent in the thalamus ( Figure 1C Figure 3 .
Discussion
The current study highlights a novel role for A 2A Rs in modulating the long term effects of nicotine treatment on α7 nAChRs. We show that the genetic deletion of adenosine A 2A Rs prevents nicotine-induced upregulation of α7, but not α4β2* nAChRs, indicating that A 2A Rs regulate the nicotinic cholinergic response to chronic nicotine administration via an α7
receptor-specific mechanism.
In control CD1 mice, 14 days of nicotine administration via osmotic minipumps increased cytisine-sensitive [ 125 I]epibatidine and [ 125 I]α-bungarotoxin binding to α4β2* and α7 nAChRs, respectively. The pattern and extent of nicotine-induced upregulation differed between the two receptor subtypes, with α4β2* nAChR upregulation showing marked regional variability and being more pronounced than that of α7 nAChRs. These observations are in complete agreement with a substantial number of reports, which have established that nAChR upregulation is a time and dose dependent phenomenon, varying quantitatively and qualitatively according to nAChR subunit composition (Marks et al., 1985; Marks et al., 1986; Pauly et al., 1989; Sanderson et al., 1993) , and cell-specific neuronal distribution (Nashmi et al., 2007) . Thus, α4β2* nAChRs, which have high affinity for nicotine, are more readily upregulated compared with low-affinity α7 nAChRs, a differential regulation that occurs in mice (Sparks and Pauly, 1999) , rats (Mugnaini et al., 2002) and humans (Teaktong et al., 2004) . For α7 nAChRs, in particular, we observed a 30% overall increase in [ 125 I]α-bungarotoxin binding sites in nicotine treated WT mice, which is consistent with the magnitude of nicotine-induced upregulation previously reported for the α7 receptor subtype by in vitro (Barrantes et al., 1995; Peng et al., 1997; Ridley et al., 2001) and in vivo studies (Pauly et al., 1991; Rasmussen and Perry, 2006) . These results render the dose of chronic nicotine used appropriate for investigating the effects of adenosine A 2A R deletion on nicotineinduced upregulation, and confirm that the overall effects of nicotine on the binding of distinct nAChR subtypes are conserved, not only among inbred , but also in outbred strains of animals. In addition, increased nAChR binding was measured at plasma levels of nicotine that are within the range reported for smokers (10-50 ng ml -1 ; Benowitz and Jacob, 1984; Russell et al., 1980) , and similar to those achieved in mice after long-term treatment with comparable doses of nicotine, administered either via osmotic minipumps (Metzger et al., 2007) , constant i.v. infusion (Marks et al., 2004) , or in the drinking water (Pekonen et al., 1993) . The current experimental design thus resulted in blood plasma levels of nicotine that are physiologically relevant to the human condition.
Unlike α4β2* nAChR binding, which was increased both in nicotine treated WT and adenosine A 2A R KO mice, the upregulation of α7 nAChRs by chronic nicotine was abolished in A 2A R KO animals. This effect is unlikely to be caused by genotype-induced differences in the availability of nicotine to the systemic circulation, as plasma nicotine and cotinine concentrations were similar in WT and KO mice, indicating that the deletion of A 2A Rs does not affect nicotine metabolism. Moreover, the specific effects of A 2A R deletion on the upregulation of α7 nAChRs cannot be related to developmental compensatory alterations in nAChR binding levels, as the distribution and densities of both α7 and α4β2* nAChRs were identical in drug-naïve or untreated control and mutant mice. These observations suggest that the effects of A 2A Rs on α7 receptor regulation are not exerted tonically, but require activation of the nicotinic cholinergic system by nicotine. Our results thus point towards the existence of specific, nicotine-induced interactions of adenosine A 2A Rs with α7, but not α4β2* nAChRs.
Although the upregulation of nAChR binding constitutes a profound and well-documented neurochemical adaptation to prolonged nicotine exposure, the exact mechanisms underlying the phenomenon are still the subject of intense investigation. It is becoming increasingly accepted, however, that distinct molecular mechanisms underpin the regulation of α4β2* vs.
α7 nAChRs by chronic nicotine. Thus, while changes in conformation, stoichiometry, or β2 nicotinic subunit chaperoning have been implicated in the upregulation of α4β2* nAChRs (Govind et al., 2009; Govind et al., 2012; Lester et al., 2009) , similar nicotine-induced alterations do not mediate the upregulation of homopentameric α7 nAChRs. Instead, increases in α7, but not α4β2* nAChRs, have been shown to require protein synthesis and glycosylation in cultured cortical neurons (Kawai and Berg, 2001) , further suggesting that different molecular mechanisms may underlie the upregulation of distinct nAChR subtypes. In this context, the present study clearly demonstrates that A 2A Rs are specifically involved in the mechanism of nicotine-induced α7, but not α4β2* receptor upregulation.
The reason for this discrepancy is unclear, but it is highly likely to involve alterations downstream of the adenosine A 2A R. One such mechanism involves the brain-derived neurotrophic factor (BDNF). The link between A 2A Rs and BDNF is well-documented, with evidence showing that A 2A R activation is necessary both for regulating the expression and release of BDNF in the brain, and mediating BDNF's effects on synaptic plasticity (reviewed in Sebastiao and Ribeiro, 2009 ). In neurons cultured from the hippocampus and the ciliary ganglion, BDNF is known to upregulate the intracellular and surface pools of α7, but not β2* nAChRs (Massey et al., 2006; Zhou et al., 2004) . In addition, the interplay of A 2A Rs with BDNF and α7 nAChRs is evidenced in the fact that adenosine deaminase or A 2A R antagonists abolish the effects of BDNF on α7 nAChR function (Fernandes et al., 2008) . Taken together, these studies suggest that mice lacking adenosine A 2A Rs may have deficits in BDNFdependent mechanisms that are specifically involved in nicotine-induced α7 nAChR upregulation. Interestingly, chronic nicotine treatment has been shown to elevate the expression or the levels of BDNF in the cortex, hippocampus and the amygdala (Aydin et al., 2012; Czubak et al., 2009; Kenny et al., 2000) . We observed that in the above brain regions nicotine-induced α7 nAChR upregulation was more pronounced in WT vs. A 2A R KO mice, whereas in the ventral tegmental area, where chronic nicotine administration does not affect BDNF levels (Kivinummi et al., 2011) , the effects of A 2A R deletion were less evident, thus providing further support to our suggestion.
Although the involvement of adenosine A 2A Rs in nicotine reinforcement (Castane et al., 2006) and withdrawal (Grieder et al., 2012) has been illustrated using mice with complete and permanent inactivation of the A 2A R gene, little is currently known about the contribution of α7 nAChR upregulation to nicotine's long-term behavioural effects. Neuroplastic alterations involving α7 and not β2* nAChRs, have been shown to mediate the effects of prolonged nicotine exposure on novelty-seeking behaviour (Besson et al., 2007) . In addition, α7 nAChRs play a pivotal role in sustaining nicotine's persistent effect on dopamine neuron excitability and, consequently, on nicotine reinforcement (Mansvelder et al., 2002; Mansvelder and McGehee, 2000) . Moreover, the manifestation of the somatic symptoms of nicotine withdrawal requires the expression of α7, but not β2* nAChRs (Besson et al., 2006; Salas et al., 2007) . As a result, the discovery that A 2A Rs modulate the response of α7 nAChRs to chronic nicotine is likely to have important implications for intervening in nicotine-induced behaviours that involve this receptor subtype, including reinforcement and dependence. In addition to nicotine-induced behaviour, α7 nAChRs have been aetiologically implicated in human neuropathology, most notably in schizophrenia (Olincy and Freedman, 2012) .
Considerable evidence indicates that the high prevalence of smoking in schizophrenics can be partly attributed to the cognitive enhancing properties of nicotine, and thus to nicotine's efficacy in alleviating the cognitive symptoms of schizophrenia (Ochoa and LasaldeDominicci, 2007 ). Nicotine's effects on cognition are known to be mediated via α7 nAChRs (Mansvelder et al., 2009) . Moreover, smoking has been shown to restore α7 receptor expression in the hippocampus of schizophrenic patients to control levels (Mexal et al., 2010) , suggesting a prominent role for α7 nAChR upregulation in the procognitive effect of nicotine.
Indeed, the beneficial effects of various α7 agonists on cognition have been closely associated with their ability to induce α7 nAChR upregulation (Christensen et al., 2010) . It is thus intriguing to postulate that a pharmacotherapeutic approach which would enhance α7 nAChR upregulation, such as A 2A R agonism, might further improve the effectiveness of α7 agonists in controlling the cognitive deficits in schizophrenia. In support of this suggestion, independent clinical and preclinical studies reveal that both dysfunction of the α7 nAChR (AhnAllen, 2012), and a reduced adenosinergic tone at A 2A Rs (Boison et al., 2012) contribute to the cognitive symptoms of the disorder.
In conclusion, we have shown that the genetic deletion of adenosine A 2A Rs prevents nicotineinduced upregulation of α7, but not α4β2* nAChRs. This modulatory effect is specific to α7 nAChRs, it occurs at plasma levels of nicotine that are relevant to the human condition, and it is not due to compensatory developmental alterations in nAChR binding levels. These Similarly, there was no effect of genotype on homopentameric, α7 nAChR binding levels. 7.6 ± 2.2 13.5 ± 2.9 8.8 ± 1.9 9.9 ± 2.3 76. 
